United Therapeutics Board Authorizes Additional $2 Billion Share Buyback
Bitget2026/10/22 11:03- United Therapeutics' board authorized an additional $2 billion common stock repurchase program, available through October 21, 2027.
- An accelerated share repurchase transaction entered into in September 2026 is scheduled to end in the fourth quarter of 2026.
- The existing transaction will not reduce the new authorization, which carries no minimum purchase requirement.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Morgan Stanley: AI capital expenditure may reach 10 to 15 trillions USD in the next 10 years
Morgan Stanley stated that capital expenditure in the artificial intelligence (AI) sector could reach $10-15 trillions over the next decade.

Morgan Stanley: Apple's target price lowered to $350

Autoliv completes acquisition of MCF Safety Belts
Refining profits surge and oil prices soar; Saudi Aramco Q3 profits grow by 9% and maintains a dividend of 21.9 billions USD.
Driven by rising refining profits and oil prices, Saudi Aramco's third-quarter profits increased by 9%.